Table 3 Baseline intake of medications in each cohort
N =251/group | Â | Group A (RA) | Group B (DM) | Group C (GP) | P, all three | P, A versus C |
|---|---|---|---|---|---|---|
Medications | Â | Â | Â | Â | Â | Â |
RA | MTX | 126 (50%) | N/A | N/A | -- | -- |
| Â | HCQ | 92 (37%) | N/A | N/A | -- | -- |
| Â | PDN | 86 (34%) | N/A | N/A | -- | -- |
| Â | TNF | 96 (38%) | N/A | N/A | -- | -- |
DM | Insulin | N/A | 100 (40%) | N/A | -- | -- |
| Â | Metformin | N/A | 132 (53%) | N/A | -- | -- |
NSAIDs | Â | 74 (29%) | 43 (17%) | 51 (20%) | 0.003 | 0.02 |
Anti-HTN | Â | 66 (26%) | 180 (72%) | 86 (34%) | < 0.0001 | 0.052 |
Statin | Â | 23 (9%) | 162 (65%) | 38 (15%) | < 0.0001 | 0.055 |
ASA | 81 mg | 22 (9%) | 93 (37%) | 33 (13%) | < 0.0001 | 0.12 |
| Â | > 81 mg | 5 (2%) | 16 (6%) | 6 (2%) | 0.01 | 0.76 |